Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Howard

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
JAMA Neurology|April 27, 2026
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical TrialFrancesco Saccà, Gino Gialdini, James F Howard, et al.
Physical Medicine and Rehabilitation Clinics of North America|January 14, 2012
The paradox of muscle hypertrophy in muscular dystrophyJoe N Kornegay, Martin K Childers, Daniel J Bogan, et al.
Archives of Physical Medicine and Rehabilitation|January 11, 2005
Distal symmetrical polyneuropathy: a definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitationJohn D England, Gary S Gronseth, Gary Franklin, et al.
The Journal of Clinical Investigation|September 18, 2018
Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitmentDenise E Allard, Yan Wang, Jian Joel Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2022
Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunityYan Wang, Lily Guo, Xihui Yin, et al.
Muscle & Nerve|December 9, 2020
Reduced plasmablast frequency is associated with seronegative myasthenia gravisJeffrey T Guptill, Richard Barfield, Cliburn Chan, et al.
Neurology. Clinical Practice|July 9, 2026
Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness MethodPushpa Narayanaswami, Renato Mantegazza, Carolina Barnett-Tapia, et al.
Muscle & Nerve|February 16, 2019
Long-term safety and efficacy of eculizumab in generalized myasthenia gravisSrikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
JAMA Neurology|April 27, 2026
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical TrialFrancesco Saccà, Gino Gialdini, James F Howard, et al.
Physical Medicine and Rehabilitation Clinics of North America|January 14, 2012
The paradox of muscle hypertrophy in muscular dystrophyJoe N Kornegay, Martin K Childers, Daniel J Bogan, et al.
Archives of Physical Medicine and Rehabilitation|January 11, 2005
Distal symmetrical polyneuropathy: a definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitationJohn D England, Gary S Gronseth, Gary Franklin, et al.
The Journal of Clinical Investigation|September 18, 2018
Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitmentDenise E Allard, Yan Wang, Jian Joel Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2022
Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunityYan Wang, Lily Guo, Xihui Yin, et al.
Muscle & Nerve|December 9, 2020
Reduced plasmablast frequency is associated with seronegative myasthenia gravisJeffrey T Guptill, Richard Barfield, Cliburn Chan, et al.
Neurology. Clinical Practice|July 9, 2026
Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness MethodPushpa Narayanaswami, Renato Mantegazza, Carolina Barnett-Tapia, et al.
Muscle & Nerve|February 16, 2019
Long-term safety and efficacy of eculizumab in generalized myasthenia gravisSrikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Pageof 12